Starting January 1st, thousands of asthma sufferers in the U.S. will no longer have access to refills of the popular inhaler Flovent, which has been on the market for almost 30 years. Manufacturer GSK has discontinued both the inhalation aerosol and inhalation powder versions of Flovent and replaced them with an authorized generic called fluticasone. The decision to discontinue the brand-name inhaler comes as its price has increased by nearly 50% since 2014, making it vulnerable to new Medicaid penalties. By introducing the authorized generic, GSK can avoid these penalties and continue to profit from the product.
Source link
GSK Flovent asthma inhalers replaced by authorized generics
